Results 111 to 120 of about 765,112 (149)

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

open access: yesHaematologica, 2021
Burcu Aslan   +6 more
doaj   +1 more source

Role of Bruton's Tyrosine Kinase in B Cell Development

open access: yesClinical and Developmental Immunology, 2001
Alex Maas, Rudolf W. Hendriks
doaj   +1 more source

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

open access: yesHemaSphere, 2023
Michael Gulrajani   +8 more
doaj   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini   +19 more
wiley   +1 more source

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

P686: A PHASE 1 FIRST IN-HUMAN STUDY OF BGB-16673, A BRUTON TYROSINE KINASE PROTEIN DEGRADER, IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES (TRIAL IN PROGRESS)

open access: yesHemaSphere, 2022
C. S. Tam   +8 more
doaj   +1 more source

Remibrutinib as a Therapeutic Option for Solar Urticaria

open access: yes
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares   +3 more
wiley   +1 more source

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)

open access: yesHemaSphere, 2023
Xiaoyu Feng   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy